Four major regulatory frameworks are converging simultaneously — each with distinct requirements, timelines, and enforcement mechanisms. USDM’s unified compliance approach maps a single AI system across all four in one integrated assessment.
FDA’s Computer Software Assurance framework replaces documentation-heavy CSV with a risk-based, critical-thinking approach — establishing the primary validation pathway for AI/ML systems in GxP environments. The FDA AI/ML Action Plan provides supplemental guidance on AI in drug development, safety monitoring, and SaMD.
21 CFR Part 11 / Annex 11 compliance for AI-generated records
CSA guidance finalized 2022 · AI/ML Action Plan active · Enforcement ongoing
Warning Letter · Product approval delay · Market access restriction
The EU AI Act establishes the world’s first comprehensive AI regulatory framework — with high-risk classification directly applicable to AI systems in medical devices, pharmacovigilance, clinical decision support, and regulated quality processes. Life sciences companies face the most intensive compliance obligations under the Act.
Prohibited practices: Feb 2025 (active) · High-risk obligations: Aug 2026 · Full application: Aug 2027
Up to €35M or 7% of global annual turnover · Market access restriction
ISO 42001:2023 establishes international requirements for an AI Management System (AIMS) — providing the governance infrastructure that organizations need to implement, maintain, and continually improve responsible AI practices. Aligns closely with EU AI Act requirements and provides the operational backbone for TRUST-AI.
Published December 2023 · Emerging as de facto governance standard · EU AI Act alignment confirmed
No direct financial penalty · Provides compliance evidence for EU AI Act and FDA requirements
GAMP 5’s second edition explicitly addresses AI/ML systems in pharmaceutical manufacturing and quality environments — establishing Category 5 as the classification for AI systems with bespoke algorithms. Provides updated guidance on data integrity, life cycle management, and validation evidence for AI in GxP.
GAMP 5 2nd Ed. published 2022 · Actively referenced in FDA inspections · Industry standard
No direct financial penalty · Inspection finding risk · Part of FDA/EMA inspection expectations
EU AI Act officially in force. Six-month countdown begins for prohibited practice rules and GPAI model obligations.
Banned AI applications prohibited. General-purpose AI model obligations in force. European AI Office established and operational.
Full high-risk AI system compliance required: conformity assessments, Annex IV documentation, human oversight mechanisms, post-market monitoring. Life sciences AI in QMS, PV, SaMD contexts must comply. This is the critical deadline for most life sciences organizations.
Copilot, ChatGPT, departmental AI platforms, and vendor-embedded AI are in active use in GxP environments at most life sciences organizations — without Quality awareness, validation evidence, or documented oversight. FDA inspectors are now specifically trained to identify undisclosed AI in GxP processes. This is the fastest-growing source of unexpected inspection findings heading into 2026–2027 inspection cycles. USDM’s first engagement with most clients begins with an AI system inventory — and the list is always longer than expected.